About Velvio

Velvio develops new medicines to restore organ repair functions for treatment in Neurodegeneration and Pulmonary Fibrosis, first in Orphan diseases Amyotrophic Lateral Sclerosis (ALS) and Idiopathic pulmonary Fibrosis (IPF). Furthermore, Velvio targets to enhance clinical responses of solid tumors to Immune-Oncology treatment concepts.

Based on our highly promising pre-clinical pipeline, we are ready to go “first in man” in ALS, in IPF we are about to finish preclinical in vivo drug development.


Velvio GmbH

Am Biopark 11
93053 Regensburg | Germany

+49 (0) 941 463 747-37